Vol 6, No 3 (2020)
Review paper
Published online: 2020-09-30
Page views 937
Article views/downloads 44
Get Citation

Connect on Social Media

Connect on Social Media

Risk of cancers in patients with mastocytosis

Maciej Milewczyk1, Michał Joskowski1, Justyna Czarny2, Magdalena Lange2
Forum Dermatologicum 2020;6(3):77-81.

Abstract

Mastocytosis is a heterogeneous disease characterized by clonal proliferation and abnormal mast cells accumulation in various tissues, particularly in the skin and bone marrow. The clinical spectrum of systemic mastocytosis (SM) includes, among others, SM with associated hematologic neoplasm (SM-AHD) and mast cell leukemia (MCL). However, little is known about the incidence and pathogenesis of non-hematological malignancies in patients with mastocytosis. Increased risk of carcinogenesis in this group of patients could be associated with treatment methods of this disease. PUVA-therapy, as one of cutaneous mastocytosis (CM) treatment options, and the influence of immunosuppression and cytoreductive treatment in advanced forms of SM may influence carcinogenesis. According to the recent publications, increased risk of malignant neoplasms of the skin and internal organs in patients with mastocytosis has been observed. The current state of knowledge suggests a holistic approach and the need of oncological assessment of mastocytosis patients, particularly as far as malignant melanoma is concerned.

Article available in PDF format

Add to basket: 49.00 PLN

Aready have access?

References

  1. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017; 129(11): 1420–1427.
  2. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007; 37(6): 435–453.
  3. Pardanani A. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Am J Hematol. 2019; 94(3): 363–377.
  4. Lange M, Flisiak I, Kapinska-Mrowiecka ML, et al. Mastocytosis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Przegl Dermatol. 2018; 105(3): 358–383.
  5. Hartmann K, Escribano L, Grattan C, et al. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016; 137(1): 35–45.
  6. Valent P, Akin C, Gleixner KV, et al. Multidisciplinary challenges in mastocytosis and how to address with personalized medicine approaches. Int J Mol Sci. 2019; 20(12).
  7. Broesby-Olsen S, Dybedal I, Gülen T, et al. Multidisciplinary management of mastocytosis: Nordic Expert Group consensus. Acta Derm Venereol. 2016; 96(5): 602–612.
  8. Wagner N, Staubach P. Mastocytosis - pathogenesis, clinical manifestation and treatment. J Dtsch Dermatol Ges. 2018; 16(1): 42–57.
  9. Czarny J, Lange M, Ługowska-Umer H, et al. Cutaneous mastocytosis treatment: strategies, limitations and perspectives. Postepy Dermatol Alergol. 2018; 35(6): 541–545.
  10. Siebenhaar F, Akin C, Bindslev-Jensen C, et al. Treatment strategies in mastocytosis. Immunol Allergy Clin North Am. 2014; 34(2): 433–447.
  11. Obtułowicz A, Pirowska MM, Woźniacka A, et al. Suitability of tryptase concentration determination during PUVA therapy in patients with cutaneous and systemic mastocytosis. Przegl Dermatol. 2018; 105(1): 41–50.
  12. Siiskonen H, Smorodchenko A, Krause K, et al. Ultraviolet radiation and skin mast cells: Effects, mechanisms and relevance for skin diseases. Exp Dermatol. 2018; 27(1): 3–8.
  13. Brazzelli V, Grassi S, Merante S, et al. Narrow-band UVB phototherapy and psoralen-ultraviolet A photochemotherapy in the treatment of cutaneous mastocytosis: a study in 20 patients. Photodermatol Photoimmunol Photomed. 2016; 32(5-6): 238–246.
  14. Placek W, Kaszuba A, Lesiak A, et al. Phototherapy and photochemotherapy in dermatology. Recommendations of the Polish Dermatological Society. Dermatology Review. 2019; 106(3): 237–256.
  15. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998; 351(9103): 623–628.
  16. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer. 2009; 125(8): 1747–1754.
  17. Wimmer CD, Rentsch M, Crispin A, et al. The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int. 2007; 71(12): 1271–1278.
  18. Broesby-Olsen S, Farkas DK, Vestergaard H, et al. Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: A nationwide population-based study. Am J Hematol. 2016; 91(11): 1069–1075.
  19. Molderings GJ, Zienkiewicz T, Homann J, et al. Risk of solid cancer in patients with mast cell activation syndrome: Results from Germany and USA. F1000Res. 2017; 6: 1889.
  20. Wilcock A, Bahri R, Bulfone-Paus S, et al. Mast cell disorders: From infancy to maturity. Allergy. 2019; 74(1): 53–63.
  21. Kopeć-Szlęzak J. Mastocyty i ich znaczenie w procesach odpornościowych i nowotworowych. J Transf Med. 2015; 8: 49–59.
  22. Tóth-Jakatics R, Jimi S, Takebayashi S, et al. Cutaneous malignant melanoma: correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor. Hum Pathol. 2000; 31(8): 955–960.
  23. Todd P, Garioch J, Seywright M, et al. Malignant melanoma and systemic mastocytosis--a possible association? Clin Exp Dermatol. 1991; 16(6): 455–457.
  24. Okun M, Bhawan J. Combined melanocytoma-mastocytoma in a case of nodular mastocytosis. Journal of the American Academy of Dermatology. 1979; 1(4): 338–347.
  25. Hägglund H, Sander B, Gülen T, et al. Increased risk of malignant melanoma in patients with systemic mastocytosis? Acta Derm Venereol. 2014; 94(5): 583–584.
  26. Donati P, Paolino G, Donati M, et al. Cutaneous mastocytosis combined with eruptive melanocytic nevi and melanoma. Coincidence or a linkage in the pathogenesis? J Dermatol Case Rep. 2014; 8(3): 70–74.
  27. Longley BJ, Morganroth GS, Tyrrell L, et al. Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis . New Engl J Med. 1993; 18(328): 1302–1307.
  28. Vojvodic A, Vlaskovic-Jovicevic T, Vojvodic P, et al. Melanoma and mastocytosis. Open Access Maced J Med Sci. 2019; 7(18): 3050–3052.